151. Remote monitoring of cardiac implantable electronic devices and disease management.
- Author
-
Varma N, Braunschweig F, Burri H, Hindricks G, Linz D, Michowitz Y, Ricci RP, and Nielsen JC
- Subjects
- Humans, Electronics, Heart, Technology, Disease Management, Cardiovascular Agents
- Abstract
This reviews the transition of remote monitoring of patients with cardiac electronic implantable devices from curiosity to standard of care. This has been delivered by technology evolution from patient-activated remote interrogations at appointed intervals to continuous monitoring that automatically flags clinically actionable information to the clinic for review. This model has facilitated follow-up and received professional society recommendations. Additionally, continuous monitoring has provided a new level of granularity of diagnostic data enabling extension of patient management from device to disease management. This ushers in an era of digital medicine with wider applications in cardiovascular medicine., Competing Interests: Conflict of interest: N.V.: Research/Consulting for Abbott, Biotronik, and Impulse Dynamics; Pacemate; Implicity; and JB Research/Consulting Boston Scientific, Zoll; F.B.: Medtronic, Biotronik, Biosense Webster, Impulse Dynamics, Novartis, Orion, Boehringer, Astra Zeneca, and Pfizer; H.B.: Abbott, Biotronik, Boston Scientific, Medtronic, and Microport. G.H.: (paid to Heart Center Leipzig): Biosense and Boston Scientific; D.L.: none; Y.M.: none; R.P.R.: minor consultancy fees for Abbott and Dompé Farmaceutici S.p.A.; J.C.N.: institutional research grants from the Novo Nordisk Foundation outside this work., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF